Johnson & Johnson

Latest Headlines

Latest Headlines

J&J moves forward with next-gen insulin delivery

Johnson & Johnson's Animas is moving forward with its investigational artificial pancreas--an insulin-delivery device that can detect blood glucose in the body and automatically normalize levels.

Bloomberg: J&J close to wrapping Risperdal probe for up to $2.2B

Bloomberg  reports that J&J is close to settling with the U.S. Justice Department for up to $2.2 billion. At that amount, the settlement would rank second to Pfizer's $2.3 billion off-label marketing deal from 2009.

J&J's Animas will advance a second artificial pancreas trial

Johnson & Johnson's ($JNJ) Animas will advance a second feasibility study for its artificial pancreas system, after the system generated promising results from first trial effort involving 13 adult patients with Type 1 diabetes.

UPDATED: ADA roundup: J&J's diabetes pioneer edges out Januvia in Phase III

Johnson & Johnson didn't disappoint close observers of the diabetes drug development field with its battery of late-stage results for the experimental diabetes drug canagliflozin.

J&J grabs ADA spotlight for new diabetes drug

Determined to build its stake in the fast-growing diabetes market, Johnson & Johnson plans to showcase late-stage data this weekend on its promising SGLT2 drug candidate that has drawn both praise and skepticism from clinicians and analysts.

Shelves still bare of Tylenol products, stores lament recalls

Private-label products still take the place of Tylenol and other McNeil products on store shelves, and patients aren't happy about it.

J&J/Ethicon to stop selling four vaginal mesh implants

Johnson & Johnson/Ethicon ($JNJ) will stop selling four vaginal mesh implants in the face of hundreds of lawsuits challenging the products' safety.

ASCO: Data on J&J, Medivation meds spell trouble for Provenge

After last year's debut of Dendreon's immunotherapy Provenge and Johnson & Johnson's pill Zytiga, prostate cancer treatment may be in for another big shake-up.

J&J should split itself three ways, Goldman analyst says

As Goldman Sachs analyst Jami Rubin sees it, there's another major drugmaker whose whole is worth less than the sum of its parts. This time, it's Johnson & Johnson--and Rubin figures it would be worth more split three ways.

ASCO Roundup: Key news from Bayer, Aveo, J&J and Seattle Genetics

Bayer looks to secure blockbuster status for regorafenib; J&J demonstrated impressive results among pre-chemo prostate cancer patients; Aveo raises the flag for tivozanib; Seattle Genetics plans to look at new indications for Adcetris.